by Primrose Bio | Nov 11, 2025 | Scientific Posters
ABSTRACT: Amber suppression technology has matured over the last 25 years, enabling incorporation of non-canonical amino acids (ncAAs) that allow targeted conjugation and expanded therapeutic functionality. Despite its potential, implementation has been limited by... 
by Primrose Bio | Nov 10, 2025 | Featured, Press
Maximize capping efficiency and minimize double-stranded RNA (“dsRNA”) in the manufacturing of self-amplifying mRNA San Diego, Calif. Nov. 10, 2025 – Primrose Bio, Inc. (“Primrose”), a company with proprietary therapeutic manufacturing technologies, today announced... 
by Primrose Bio | Nov 4, 2025 | Events
Primrose Bio is in Portugal for PEGS Europe: Protein & Antibody Engineering Summit! Join our President & COO Diane Retallack for a presentation on “Pfast™ Protein Expression Workflows: Accelerating Biotherapeutic Screening and Manufacturing... 
by Primrose Bio | Oct 1, 2025 | Featured, Press
San Diego, Calif. October 1, 2025 – Primrose Bio, Inc. (“Primrose”) announced today the appointment of Andrew “Drew” Burch as its Chief Executive Officer, and member of the Board of Directors. Drew succeeds Helge Zieler, PhD, who will move into a new role of Chief... 
by Primrose Bio | Sep 12, 2025 | Events
Primrose Bio is participating in the 4th Annual mRNA-Based Therapeutics Summit, part of the World RNA Events Series by Hanson Wade, taking place September 23–25 in Boston, MA. On Day 2, Patrik Engström, PhD, presents at 11:30 AM on:“Engineered RNA...